Zenith to reach new heights with expanded reach in the U.S.

Ireland-based life science tech services firm Zenith Technologies is boosting its U.S. presence with two new offices on the West Coast.

In a statement, the Cork-headquartered company said it was expanding its global footprint as a result of “greater demand for its automation, process control and serialization technology support services.”

Zenith, which has been in the U.S. for a decade since the opening of its first American site in Pennsylvania, will now look west with its latest offices in Oakland and San Diego.

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

The idea is for the firm to deliver a more localized service to its North American customers, the company said, which include small and mid-sized pharma and biotech companies as well as CMOs and Big Pharma firms.

Mike Smith, U.S. sales manager at Zenith Technologies, said: “We are looking forward to bolstering our US presence with the opening of these two new sites as it means we can provide complete coverage of service in the US from coast to coast.

“Expanding into such high growth areas for the life science and biotechnology industry means it is a really exciting time for our company and a great way to mark a decade of presence in North America.”

Both offices are designed as a hub to help the company with its ongoing projects, as well as for back office assistance and managed services.

- check out the release

Suggested Articles

Clinical trial firm Phesi’s new report is some grim reading for the life science industry: Studies for new drugs are still suffering.

Tempus fugit: And time especially flies when it comes clinical trials. Covance is teaming up with the suitably named Tempus to clip its wings.

PPD has raised its quarterly guidance after weathering the COVID-19 storm and is immediately making a secondary offering of 38 million shares.